Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-Assisted Lifestyle Intervention vs Tirzepatide in Obesity and Newly Diagnosed Type 2 Diabetes
NCT07697391Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Percent Change in Body Weight at 52 weeks. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT07697391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697391.